Clinical trial
Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C
NCT00265642 · ANRS, Emerging Infectious Diseases, Other · Completed
Key facts
| NCT number | NCT00265642 |
|---|---|
| Title | Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C |
| Official title | Study of the Effects of a Sartan on Hepatic Fibrosis Progression in Chronic Viral Hepatitis C |
| Acronym | Fibrosar |
| Lead sponsor | ANRS, Emerging Infectious Diseases, Other |
| Collaborators | Sanofi Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic |
| Intervention type | Drug |
| Interventions | Irbesartan, placebo |
| Enrollment | 166 |
| Start date | Oct 1, 2006 |
| Primary completion | Apr 1, 2013 |
| Completion | Nov 1, 2013 |
| First posted | Dec 15, 2005 |
| Last update posted | Feb 7, 2014 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: